Jonas Kath
@therealjonaskath.bsky.social
Physician Scientist | Genome Engineering | CAR T cells
Reposted by Jonas Kath
“Good things take time”
Allogeneic Treg do not prevent their own rejection in immunocompetent hosts - HLA matching or HLA editing required for optional function!
A beautiful collaboration with Fadi Issa & Joanna Hester’s team @ox.ac.uk. @dlwagnerlabs.bsky.social
Allogeneic Treg do not prevent their own rejection in immunocompetent hosts - HLA matching or HLA editing required for optional function!
A beautiful collaboration with Fadi Issa & Joanna Hester’s team @ox.ac.uk. @dlwagnerlabs.bsky.social
HLA matching or CRISPR editing HLA-I/II enables engraftment & function of allo human Treg therapy in a humanized mouse transplantation model @natcomms.nature.com @dlwagner.bsky.social @bcmhouston.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
October 13, 2025 at 9:30 PM
“Good things take time”
Allogeneic Treg do not prevent their own rejection in immunocompetent hosts - HLA matching or HLA editing required for optional function!
A beautiful collaboration with Fadi Issa & Joanna Hester’s team @ox.ac.uk. @dlwagnerlabs.bsky.social
Allogeneic Treg do not prevent their own rejection in immunocompetent hosts - HLA matching or HLA editing required for optional function!
A beautiful collaboration with Fadi Issa & Joanna Hester’s team @ox.ac.uk. @dlwagnerlabs.bsky.social
Reposted by Jonas Kath
@dlwagnerlabs.bsky.social on tour! 🌍🇩🇪🇺🇸
We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸
Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸
Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
October 12, 2025 at 1:45 PM
@dlwagnerlabs.bsky.social on tour! 🌍🇩🇪🇺🇸
We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸
Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸
Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
Reposted by Jonas Kath
Our team is on their way to the ESGCT conference 2025! Excited for this upcoming week full of science, talks, and inspiring discussions with the cell & gene therapy community!
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
October 5, 2025 at 8:51 PM
Our team is on their way to the ESGCT conference 2025! Excited for this upcoming week full of science, talks, and inspiring discussions with the cell & gene therapy community!
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
Super-large targeted Knock-Ins in primary T cells, with multigene inserts >8kb, in a single reaction. HOW?? 🙀
Combine simple CRISPR-HDR & Integrases for one-pot PASTA🍝
= Programmable And Site-specific Transgene Addition. 😎
Combine simple CRISPR-HDR & Integrases for one-pot PASTA🍝
= Programmable And Site-specific Transgene Addition. 😎
September 19, 2025 at 1:33 PM
Super-large targeted Knock-Ins in primary T cells, with multigene inserts >8kb, in a single reaction. HOW?? 🙀
Combine simple CRISPR-HDR & Integrases for one-pot PASTA🍝
= Programmable And Site-specific Transgene Addition. 😎
Combine simple CRISPR-HDR & Integrases for one-pot PASTA🍝
= Programmable And Site-specific Transgene Addition. 😎
Reposted by Jonas Kath
Lab History pt. 4 (2024)
What could be BETTER THAN TRAC KNOCK-IN ??
CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...
What could be BETTER THAN TRAC KNOCK-IN ??
CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...
September 18, 2025 at 12:29 AM
Lab History pt. 4 (2024)
What could be BETTER THAN TRAC KNOCK-IN ??
CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...
What could be BETTER THAN TRAC KNOCK-IN ??
CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...
Reposted by Jonas Kath
Lab History pt. 3 (2023)
Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!
HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.
Published in Blood Advances 🔗 ashpublications.org/bloodadvance...
Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!
HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.
Published in Blood Advances 🔗 ashpublications.org/bloodadvance...
September 18, 2025 at 12:23 AM
Lab History pt. 3 (2023)
Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!
HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.
Published in Blood Advances 🔗 ashpublications.org/bloodadvance...
Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!
HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.
Published in Blood Advances 🔗 ashpublications.org/bloodadvance...
How everything started. My first 1st 🤟
Lab History pt. 1
2022 – 🚨 Our first paper is out! 🚨
virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR.
➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation
🧬 A key step toward scalable, non-viral CAR-T cell therapies.
DOI: 10.1016/j.omtm.2022.03.018
2022 – 🚨 Our first paper is out! 🚨
virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR.
➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation
🧬 A key step toward scalable, non-viral CAR-T cell therapies.
DOI: 10.1016/j.omtm.2022.03.018
September 19, 2025 at 3:10 AM
How everything started. My first 1st 🤟